Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | TRPM5 | Q9NZQ8 | 6/20 | 0.37 |
| ▸ | TRPM4 | Q8TD43 | 4/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704205 | 0.87 | TRPM5 (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL4702666 | 0.80 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5092292 | 0.78 | FFAR1 (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3855315 | 0.78 | ACHE (0.39) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6808079 | 0.77 | SLC6A4 (0.40) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5090626 | 0.76 | HTR1D (0.46) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL4706203 | 0.75 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL5090659 | 0.75 | TAAR1 (0.32) | HTR2CHTR2AHTR2B | |
| SCHEMBL5097822 | 0.74 | MAP3K14 (0.42) | ADRA2AADRA2BADRA2CTRPM5TRPM4 | |
| SCHEMBL10696858 | 0.70 | HTR2C (0.44) | ADRA2AADRA2BADRA2CMDM2MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1458703-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | ADRA2A 716/4885ADRA2B 1425/4885ADRA2C 754/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | ADRA2A 492/4885ADRA2B 475/4885ADRA2C 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.